Clinical characteristics of patients with resistant hypertension: the RESIST-POL study

Journal of Human Hypertension

Volumn 27, Issue 11, 2013, Pages 678-685

  Florczak, E ^a   Prejbisz, A ^a   Szwench Pietrasz, E ^a   Sliwinski P ^b   Bielen P ^b   Klisiewicz, A ^a   Michalowska I ^a   Warchol E ^a   Januszewicz, M ^c   Kala M ^d   Witkowski, A ^a   Wiecek A ^e   Narkiewicz, K ^f   Somers, V K ^g   Januszewicz, A ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d INSTITUTE OF FORENSIC RESEARCH   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g MAYO CLINIC   (United States)

Author keywords

metabolic syndrome; obstructive sleep apnea; primary aldosteronism; renal artery stenosis; resistant hypertension

Indexed keywords

SODIUM;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; PRIMARY HYPERALDOSTERONISM; PROSPECTIVE STUDY; RESISTANT HYPERTENSION; SLEEP DISORDERED BREATHING; SODIUM EXCRETION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMORBIDITY; DEPRESSION; DRUG RESISTANCE; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLAND; PREVALENCE; PROSPECTIVE STUDIES; RENAL ARTERY OBSTRUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, OBSTRUCTIVE; TREATMENT FAILURE; YOUNG ADULT;

EID: 84885589246     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.32     Document Type: Article

References (39)

1. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898-902.
2. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-1080.
3. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14: 7-12.
4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419.
5. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012; 125: 1594-1596.
6. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642.
7. Davies RJ, Stradling JR. The relationship between neck circumference, radiographic pharyngeal anatomy, and the obstructive sleep apnoea syndrome. Eur Respir J 1990; 3: 509-514.
8. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
9. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
10. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005; 18: 805-812.
11. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3: 92-102.
12. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281.
13. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540.
14. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.
15. [Indications for imaging and percutaneous angioplasty of renal artery stenosis in patients with arterial hypertension. Statement of the Polish Society of Hypertension, Polish Society of Nephrology and Polish Cardiac Society. Kardiol Pol 2010; 68: 860-867.
16. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Technique and Scoring System from Sleep Stages of Human Subjects. US Department of Health, Education, and Welfare Public Health Service-NIH/NIND: Washington DC, 1968.
17. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667-689.
18. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
19. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlof B, Poulter NR. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011; 29: 2004-2013.
20. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2012; 26: 281-287.
21. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58: 811-817.
22. Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond) 2010; 34: 791-799.
23. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-741.
24. Gami AS, Somers VK. Obstructive sleep apnoea, metabolic syndrome, and cardiovascular outcomes. Eur Heart J 2004; 25: 709-711.
25. Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension 2010; 56: 1077-1082.
26. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010; 6: 363-368.
27. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118: 1080-1111.
28. Lloberes P, Lozano L, Sampol G, Romero O, Jurado MJ, Rios J et al. Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. J Sleep Res 2010; 19: 597-602.
29. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation 2012; 126: 1495-1510.
30. Acelajado MC, Calhoun DA. Aldosteronism and resistant hypertension. Int J Hypertens 2011; 2011: 837817.
31. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007; 50: 424-431.
32. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.
33. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-1926.
34. Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007; 30: 1699-1703.
35. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130.
36. de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens 2009; 27: 1333-1340.
37. Eze-Nliam CM, Thombs BD, Lima BB, Smith CG, Ziegelstein RC. The association of depression with adherence to antihypertensive medications: a systematic review. Journal of Hypertens 2010; 28: 1785-1795.
38. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124: 1046-1058.
39. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr SC, Crowley K et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013; 34: 1204-1214.